valve

Nuevas estrategias en el territorio femoropoplíteo

Drug-Coated Balloon Angioplasty in Femoropopliteal CTOs: Intraluminal or Subintimal?

Patients with peripheral vascular disease often experience femoropopliteal compromise. It is estimated that approximately 50% of lesions in this area are chronic total occlusions (CTO). Even though success rate has improved for peripheral CTO treatments, long term clinical and technical outcomes have not been fully determined yet.&nbsp; Prior research has looked into stenting outcomes in<a href="https://solaci.org/en/2024/04/19/drug-coated-balloon-angioplasty-in-femoropopliteal-ctos-intraluminal-or-subintimal/" title="Read more" >...</a>

ACC 2024

ACC 2024 | SMART Trial: Self-Expanding or Balloon-Expandable TAVR in Patients with Small Aortic Annulus

Patients with severe aortic stenosis and a small aortic annulus face an increased risk of deteriorated valvular hemodynamic performance and adverse cardiovascular clinical outcomes after undergoing transcatheter aortic valve replacement (TAVR). This study, a prospective multicenter randomized trial, aimed to compare the efficacy and safety of two types of valves: the supra-annular self-expanding EVOLUT (SEV)<a href="https://solaci.org/en/2024/04/12/acc-2024-smart-trial-self-expanding-or-balloon-expandable-tavr-in-patients-with-small-aortic-annulus/" title="Read more" >...</a>

ACC 2024

ACC 2024 | RELIEVE-HF

Heart failure is characterized by increased left atrial filling pressure and venous congestion which intensify with exercise and volume burden, and makes conventional medical management hard. In this context, interatrial shunting might offer a self-regulating mechanism, as shown by the Ventura IAS study. The aim of this study was to assess the safety and efficacy<a href="https://solaci.org/en/2024/04/10/acc-2024-relieve-hf/" title="Read more" >...</a>

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

TAVR in the Different Types of Aortic Stenosis

Aortic stenosis (AS) is classified according to gradient into high flow and high gradient (D1), low flow-low gradient with reduced ejection fraction (D2), and paradoxical low flow-low gradient with conserved ejection fraction (D3). D3 AS is characterized by ≥50% ejection fraction, but with systolic volume index ≤35 ml/min. Post TAVR evolution of D2 and D3<a href="https://solaci.org/en/2024/04/05/tavr-in-the-different-types-of-aortic-stenosis/" title="Read more" >...</a>

Transcatheter Myotomy for the Treatment of the Dynamic Obstruction of the Left Ventricular Outflow Tract

Septal reduction therapies are used to mitigate the symptoms caused by dynamic left ventricular outflow tract (LVOT) obstruction and the associated mitral regurgitation (MR) that can surge in hypertrophic cardiomyopathy (HCM).&nbsp; Alternative therapies to treat LVOT obstruction include surgical procedures, i.e. surgical myotomy or myomectomy, or alcohol and radiofrequency septal ablation (intracardiac, transthoracic and endocardial,<a href="https://solaci.org/en/2024/03/24/transcatheter-myotomy-for-the-treatment-of-the-dynamic-obstruction-of-the-left-ventricular-outflow-tract/" title="Read more" >...</a>

Anillos aórticos pequeños, ¿Qué válvula deberíamos elegir?

NOTION Trial: 10 Year Outcomes, TAVR vs. SAVR in Low Risk Patients

Transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of patients with severe aortic stenosis (AS). Randomized studies have shown the benefits of TAVR for treating inoperable patients, as well as high and intermediate risk patients.&nbsp; The NOTION (Nordic Aortic Valve Intervention Trial) randomized patients with low risk severe AS to TAVR or SAVR (surgical<a href="https://solaci.org/en/2024/03/22/notion-trial-10-year-outcomes-tavr-vs-savr-in-low-risk-patients/" title="Read more" >...</a>

pacemaker marcapasos definitivo

Guidewire Pacing and Pressure Assessment in TAVR: The SAFE-TAVI Study

Currently, the number of transcatheter aortic valve replacement (TAVR) procedures is increasing as it expands towards a lower-risk younger population. Therefore, continuous technological advancement is imperative to reduce post-procedural complications. The Food and Drug Administration (FDA) has approved the SavyWire, a preformed 0.035-gauge guidewire that can perform three essential functions: 1) it facilitates prosthesis transportation<a href="https://solaci.org/en/2024/03/20/guidewire-pacing-and-pressure-assessment-in-tavr-the-safe-tavi-study/" title="Read more" >...</a>

Resultados alentadores en la válvula mitral percutánea en los pacientes complejos

TENDER Study, Evolution at One Year

The use of transcatheter mitral valve intervention for the treatment of mitral valve regurgitation (MR) continues to evolve; at present guidelines only recommend it for inoperable or high surgical risk patients.&nbsp;&nbsp;&nbsp; So far, many devices have been assessed, some of which have shown promising results, but only for poor surgical candidates.&nbsp; Researchers looked into the<a href="https://solaci.org/en/2024/03/15/tender-study-evolution-at-one-year/" title="Read more" >...</a>

Resultados a 2 años de los stents liberadores de Zotarolimus vs stents libres de polímero liberadores de Biolimus. ¿Son seguros en pacientes con alto riesgo de sangrado?

IN.PACT Outcomes at 5 Years

Over time, percutaneous coronary intervention (PCI) with drug coated balloons (DCB) have been shown more beneficial than conventional PCI. However, in many cases, stenting is required to treat suboptimal results.&nbsp; Even though several studies have looked into this scenario, long term durability still calls for research. This was a 5 year thorough analysis of the<a href="https://solaci.org/en/2024/03/09/in-pact-outcomes-at-5-years/" title="Read more" >...</a>

Relación entre calidad del vaso distal y resultados en tratamiento percutáneo de las oclusiones totales crónicas

ERCTO Registry: Current Results for Percutaneous Treatment of Chronic Total Occlusions

Chronic total occlusions (CTO) occur in up to 20% of patients undergoing diagnostic angiographic studies. Over the past two decades, the optimization of recanalization techniques, the development of new specialized devices, and improvement in operator skill have contributed to an increased procedural success rate, reaching 90%. However, specific complications such as collateral perforation and access<a href="https://solaci.org/en/2024/03/08/ercto-registry-current-results-for-percutaneous-treatment-of-chronic-total-occlusions/" title="Read more" >...</a>

Top